L
Limedix
Develops digital supply solutions for speech therapy
About Limedix
Limedix GmbH, the company behind the neolexon brand, was founded in 2017 by speech therapists Dr. Mona Späth and Dr. Hanna Jakob. The idea originated in 2013 from their direct experience in therapy rooms and through intensive research at the Ludwig-Maximilians-University in Munich. They identified a need for digital innovation to improve care for patients with speech impairments.
The company develops and distributes digital applications for speech therapy. Its flagship product is the neolexon aphasia app, which is the first speech therapy app to be included in the DiGA directory (Digital Health Applications) in Germany. This allows the app to be prescribed by doctors and reimbursed by all statutory health insurance funds.
The business model focuses on the development and sale of therapeutic and health-promoting software, which is registered as a medical device. Limedix serves patients with language disorders, such as those recovering from a stroke, and the speech therapists who treat them. The app provides a platform for patients to continue their therapy independently at home, complementing traditional face-to-face sessions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Munich, Germany
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 76.2/100
- Industry
- Health
- Sub-industry
- Medical Devices, Health Platform
- Sector
- Health Tech & Medtech, Neurology, Telemedicine, Medical Data, Spinout, Headstart (EIT Health), Digital Therapeutics, Headstart 2017 (EIT Health)
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SUPPORT PROGRAM✓Other financing | Jul 2017 | $53K | — | EIT Health | — |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | Ludwig Maximilian University of Munich | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Limedix is 3.4K monthly website visits, down 8.1% over the last three months. Limedix's team grew 35.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors5 additional known investors
EIT Health
Ludwig Maximilian University of Munich
LMU Entrepreneurship Center
WERK1
Xpreneurs
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Limedix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Limedix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.